Oxprenolol is a non-selective beta-adrenergic receptor blocker with intrinsic sympathomimetic activity (ISA), primarily used in the management of hypertension, angina pectoris, and certain cardiac arrhythmias by reducing heart rate and myocardial oxygen demand. It was developed during the expansion of beta-blocker research in the 1960s–1970s, following the introduction of early agents like propranolol, as part of efforts to create compounds with improved safety and fewer side effects such as excessive bradycardia. Oxprenolol was introduced into clinical use in the early 1970s by pharmaceutical research programs focused on cardiovascular therapeutics and became widely prescribed in several countries, particularly in Europe, for cardiovascular and anxiety-related conditions due to its partial agonist activity.
